GU Cancers 2019 | CheckMate 214 trial in RCC updates
David McDermott
Prof. David McDermott, MD, of Beth Israel Deaconess Medical Center, Boston, MA, discusses results from the Phase III Checkmate 214 trial, which brought PD1 blockers into the frontline of renal cell carcinoma (RCC) treatment. Prof. McDermott explained that nivolumab administration in combination with ipilimumab improved previously untreated RCC overall survival, when compared with sunitinib. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.
Similar topics
Related videos

Targeted screening and risk stratification of prostate cancer - updates from the IMPACT study
Rosalind Eeles

Erdafitinib and hyperphosphatemia in advanced UrC
Scott Tagawa

Kidney cancer: minimizing toxicities and hassle in adjuvant therapy
Tim Eisen

TROPHY-U-01: Initial findings
Scott Tagawa

Updates on JAVELIN renal 101: primary treatment for patients
Laurence Albiges
More from David McDermott